The global T cell antigen market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The T-cell receptor is a protein complex that is found on the surface of T cells or T lymphocytes. It is responsible for identifying fragments of antigen as peptides that are bound to major histocompatibility complex molecules. The major factor driving the demand for T cell antigen is the new product launches and drug approvals across the globe. 

For instance, in April 2019, Janssen announced that the European Medicines Agency (EMA) has granted a PRIME (PRIority MEdicines) designation for the company’s investigational B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy, JNJ-68284528 (JNJ-4528). Additionally, in March 2021, Novartis announced the approval of Kymriah (tisagenlecleucel) from the Health Sciences Authority (HSA) in Singapore. It is the first commercial chimeric antigen receptor T-cell (CAR-T) therapy that is used for the treatment of two life-threatening cancers.

Some major players in the market include Novartis AG, Merck KGaA, and Gilead Sciences Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in August 2021, Kite, a Gilead Company announced the clearance of its Investigational New Drug (IND) application for KITE-363 from the US Food and Drug Administration (FDA). It is the company’s first chimeric antigen receptor (CAR) T-cell therapy targeted against two antigens, CD19 and CD20. 

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Therapy

o By Indication

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- Novartis AG, Merck KGaA, and Gilead Sciences Inc., among others. 

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How players are addressing challenges to sustain growth?

• Where is the investment opportunity?

Global T Cell Antigen Market Report by Segment

By Therapy 

• CAR T-cell

• Tumor-Infiltrating Lymphocytes 

• Others

By Indication 

• Hematologic Malignancies

• Solid Tumors 

• Others

Global T Cell Antigen Market Report by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa